Currently, there are 385.40M common shares owned by the public and among those 377.42M shares have been available to trade.
Insiders at the company have transacted a total of 121 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 32 of these insider trades were purchases, accounting for 381,324 shares. Insider sales of the common stock occurred on 89 occasions, with total insider shares sold totaling 316,882 shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The company’s stock has a 5-day price change of 4.71% and 4.79% over the past three months. DXCM shares are trading -1.89% year to date (YTD), with the 12-month market performance up to 9.91% higher. It has a 12-month low price of $74.75 and touched a high of $139.55 over the same period. DXCM has an average intraday trading volume of 2.93 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 2.32%, -0.49%, and 7.75% respectively.
Institutional ownership of Dexcom Inc (NASDAQ: DXCM) shares accounts for 98.76% of the company’s 385.40M shares outstanding.
It has a market capitalization of $46.93B and a beta (3y monthly) value of 1.17. The stock’s trailing 12-month PE ratio is 92.88, while the earnings-per-share (ttm) stands at $1.31. The company has a PEG of 2.78 and a Quick Ratio of 2.48 with the debt-to-equity ratio at 1.25. Price movements for the stock have been influenced by the stock’s volatility, which stands at 2.97% over the week and 2.65% over the month.
Analysts forecast that Dexcom Inc (DXCM) will achieve an EPS of $0.27 for the current quarter, $0.39 for the next quarter and $2.23 for 2025. The lowest estimate earnings-per-share for the quarter is $0.21 while analysts give the company a high EPS estimate of $0.34. Comparatively, EPS for the current quarter was $0.17 a year ago. Earnings per share for the fiscal year are expected to increase by 14.93%, and 27.58% over the next financial year.
Looking at the support for the DXCM, a number of firms have released research notes about the stock. Morgan Stanley stated their Equal-Weight rating for the stock in a research note on May 30, 2023, with the firm’s price target at $131. Raymond James coverage for the Dexcom Inc (DXCM) stock in a research note released on April 17, 2023 offered a Strong Buy rating with a price target of $138. UBS was of a view on March 29, 2023 that the stock is Buy, while Wolfe Research gave the stock Outperform rating on January 26, 2023, issuing a price target of $121. Barclays on their part issued Equal Weight rating on October 18, 2022.
